Socialpost

Complete News World

SIFI presents new scientific data and releases the intraocular lens during the 40th Congress of the European Society of Cataract and Refractive Surgery

Catania, Italy, April 20 /PRNewswire/ SIFI, a world leader in ophthalmology, has announced three scientific presentations on its latest innovations during the upcoming Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), to be held in Milan, Italy, from September 16-20. These presentations will present the results of studies evaluating advanced SIFI solutions for refractive cataract surgery.

SIFI also announces the launch of Evolux™ Announces a new, advanced intraocular (IOL) monofocal lens based on a hydrophobic material and a non-refractive profile, designed to provide improved intermediate vision and equivalent vision compared to a standard monofocal IOL. Evolux® was developed on the basis of a patented technology platform and was a pioneer in expanding depth of field through wavefront technology.

Monday, September 19, paper-based free visual performance of the Well Fusion® Depth of Focus (Edof) Optical System: Mini Well® on the dominant eye and Mini Well Proxa® on the non-dominant eye after cataract surgery” (Mediterranean: Dr. Victor Cabaras) Clinical Outcomes SIFI’s unique solution for the treatment of presbyopia.

The electronic label ‘Evolux, the new standard of care with extended depth of focus in intraocular monofocal lenses’ (electronic label number: PO192) will provide preclinical results for evaluating the optical performance of SIFI’s new Evolux™ IOL.

Monday, September 19, Satellite Symposium “Advanced Solutions for Targeting Quantitative and Qualitative Outcomes in Refractive Cataract Surgery: More Possibilities for More Patients” (Speakers: Prof. Gerd U. Emilio Pedrotti, Dr. Victor Cabaras, Dr. IOL Evolux™ Advanced Monofocal and management of post-operative care after cataract surgery with Netildex® Gel, a twice-daily, preservative-free stable formulation of dexamethasone 0.1% and netilmicin 0.3%.

See also  No longer a family member of MM Warburg

The SIFI team looks forward to welcoming ophthalmologists to Stand B28 to discuss the benefits and properties of the above products, as well as Ecbirio™ and Amiriox™, two glaucoma medications recently introduced in select European markets.

INFORMATION ABOUT WELL FUSION®

Combining Mini Well® and Mini WELL PROXA® intraocular lenses, the WELL FUSION® System provides a new solution that offers cataract patients the opportunity to treat presbyopia with high-quality, glasses-free, uninterrupted vision at all distances and in all lighting conditions. .

Information about EVOLUX™

Evolux™ is an advanced monofocal IOL based on a hydrophobic material and a non-refractive profile that allows for better median vision and equivalent vision compared to a standard monofocal IOL.

Information on ™ AMIRIOX and ™ ECBIRIO

Ameriox™ (bimatoprost 0.3 mg/ml) and Ecbirio™ (bimatoprost 0.3 mg/ml + timolol 5 mg/ml) are the new monotherapy and fixed combination drops, respectively, used to lower elevated intraocular pressure in patients with chronic open-angle glaucoma. Ocular hypertension is permissible. Amyrox™ and Icaprio™ are available in a preservative-free, multi-dose formulation that protects the ocular surface and provides a longer shelf life (up to 90 days).

Information about SIFI

SIFI is a leading international ophthalmology company based in Italy, focused on ophthalmology since 1935. SIFI develops, manufactures and markets innovative therapeutic solutions for patients with eye diseases. Committed to improving patients’ quality of life through research and development, SIFI exports treatments to more than 20 countries around the world, with direct presence in Italy, Spain, France, Romania, Mexico and Turkey.

Journalism@sifigroup.com

Questions and contact:

Contacts:
Sabrina Zappia
Journalism@sifigroup.com + 393336999669
Logo – mma.prnewswire.com/media/1337809/SIFI_Logo.jpg

See also  Börse Express - Dash Hudson's product tagging solution enables brands to easily monetize Instagram content